These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 15750032

  • 1. Origin, structure, and activity in vitro and in vivo of dalbavancin.
    Malabarba A, Goldstein BP.
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii15-20. PubMed ID: 15750032
    [Abstract] [Full Text] [Related]

  • 2. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B, Sarkar C, Biswas R, Pandey S.
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [Abstract] [Full Text] [Related]

  • 3. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
    Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, White RJ, Henkel TJ.
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii25-30. PubMed ID: 15750034
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
    Gales AC, Sader HS, Jones RN.
    Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
    Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):83-7. PubMed ID: 16458124
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
    Mushtaq S, Warner M, Johnson AP, Livermore DM.
    J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
    [Abstract] [Full Text] [Related]

  • 14. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW, Bourgeois-Nicolaos N, Doucet-Populaire F.
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [Abstract] [Full Text] [Related]

  • 15. Glycopeptides: Update on an old successful antibiotic class.
    Pace JL, Yang G.
    Biochem Pharmacol; 2006 Mar 30; 71(7):968-80. PubMed ID: 16412985
    [Abstract] [Full Text] [Related]

  • 16. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
    Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP.
    Diagn Microbiol Infect Dis; 2006 Feb 30; 54(2):149-53. PubMed ID: 16426793
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK.
    Expert Rev Anti Infect Ther; 2008 Dec 30; 6(6):917-28. PubMed ID: 19053904
    [Abstract] [Full Text] [Related]

  • 19. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Dec 30; 53(4):307-10. PubMed ID: 15922534
    [Abstract] [Full Text] [Related]

  • 20. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo.
    Darouiche RO, Mansouri MD.
    J Infect; 2005 Apr 30; 50(3):206-9. PubMed ID: 15780414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.